Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 501–600 of 1,026
Piepoli, M. F., Hussain, R. I., Colet, J. C., Dosantos, R., Ferber, P. C., Jaarsma, T., & Edelmann, F. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2076 · Cited by 97
Tomasoni, D., Vishram‐Nielsen, J. K. K., Pagnesi, M., Adamo, M., Lombardi, C., Gustafsson, F., & Metra, M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13859 · Cited by 97
Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases
Yang, F., Xue, J., Wang, G., & Diao, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.999404 · Cited by 118
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure
Dietl, A., & Maack, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0347-7 · Cited by 90
Medication Dosing for Heart Failure with Reduced Ejection Fraction — Opportunities and Challenges
Marti, C. N., Fonarow, G. C., Anker, S. D., Yancy, C. W., Vaduganathan, M., Greene, S. J., Ahmed, A., Januzzi, J. L., Gheorghiade, M., Filippatos, G. S., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1351 · Cited by 90
Paolillo, S., Veglia, F., Salvioni, E., Corrà, U., Piepoli, M. F., Lagioia, R., Limongelli, G., Sinagra, G., Cattadori, G., Scardovi, A. B., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1364 · Cited by 90
Cannone, V., Cabassi, A., Volpi, R., & Burnett, J. C. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133265 · Cited by 92
“In 2014, the PARADIGM Trial demonstrated the beneficial therapeutic effect of sacubitril/valsartan (LCZ696), a combined angiotensin II receptor-neprilysin inhibitor, in subjects with heart failure with reduced ejection fraction [64].”
BackgroundEffectiveness of Sacubitril–Valsartan in Cancer Patients with Heart Failure
Martín‐Garcia, A., López‐Fernández, T., Mitroi, C. D., Chaparro‐Muñoz, M., Moliner, P., Martin‐Garcia, A. C., Martínez‐Monzonís, A., Castro, A., Lopez-Sendon, J. L., & Sánchez, P. L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12627 · Cited by 87
“Indeed, patients with a history of chemotherapy-related HFrEF less than 12 months prior were an exclusion criterion for PARADIGM-HF trial.(6)”
BackgroundResultPagel, P. S., Tawil, J. N., Boettcher, B. T., Izquierdo, D. A., Lazicki, T. J., Crystal, G. J., & Freed, J. K. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.07.016 · Cited by 98
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
Fiuzat, M., HAMO, C. E., Butler, J., Abraham, W. T., DeFilippis, E. M., Fonarow, G. C., Lindenfeld, J. M., Mentz, R. J., Psotka, M. A., Solomon, S. D., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.033 · Cited by 89
Self-citationACC/AHA/HFSA 2022 and ESC 2021 Guidelines on Heart Failure Comparison
Behnoush, A. H., Khalaji, A., Naderi, N., Ashraf, H., & von Haehling, S. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14255 · Cited by 115
Vardeny, O., Claggett, B. L., Kachadourian, J., Pearson, S. M., Desai, A. S., Packer, M., Rouleau, J. L., Zile, M. R., Swedberg, K. B., Lefkowitz, M. P., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004745 · Cited by 84
Self-citationMogensen, U. M., Gong, J., Jhund, P. S., Shen, L., Køber, L., Desai, A. S., Lefkowitz, M. P., Packer, M., Rouleau, J. L., Solomon, S. D., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1139 · Cited by 83
Self-citationHeart failure with preserved ejection fraction: present status and future directions
Yoon, S., & Eom, G. H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0323-2 · Cited by 92
Natriuretic Peptides as Inclusion Criteria in Clinical Trials
Ibrahim, N. E., Burnett, J. C., Butler, J., Camacho, A., Felker, G. M., Fiuzat, M., O’Connor, C., Solomon, S. D., Vaduganathan, M., Zile, M. R., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.12.010 · Cited by 83
Self-citationO’Meara, E., PRESCOTT, M. F., Claggett, B. L., Rouleau, J. L., Chiang, L., Solomon, S. D., Packer, M., McMurray, J. J. V., & Zile, M. R. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004446 · Cited by 98
Self-citationCABG Improves Outcomes in Patients With Ischemic Cardiomyopathy
Howlett, J. G., Stebbins, A., Petrie, M. C., Jhund, P. S., Castelvecchio, S., Cherniavsky, A., Sueta, C. A., Roy, A., Piña, I. L., Wurm, R., et al. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.04.018 · Cited by 97
Spannella, F., Giulietti, F., Filipponi, A., & Sarzani, R. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13002 · Cited by 90
Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments
Kario, K., & Williams, B. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17440 · Cited by 82
Butt, J. H., Docherty, K. F., Jhund, P. S., de Boer, R. A., Böhm, M., Desai, A. S., Howlett, J. G., Inzucchi, S. E., Kosiborod, M., Martínez, F. A., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2381 · Cited by 90
Self-citationThe Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
Schuett, K. A., Marx, N., & Lehrke, M. (2023) · Circulation Research · doi:10.1161/circresaha.122.321748 · Cited by 100
Mongirdienė, A., Skrodenis, L., Varoneckaitė, L., Mierkytė, G., & Gerulis, J. (2022) · Biomedicines · doi:10.3390/biomedicines10030602 · Cited by 90
Marin‐Neto, J. A., Rassi, A., de Oliveira, G. M. M., Correia, L. C. L., Ramos, A. N., Luquetti, A. O., Hasslocher‐Moreno, A. M., de Sousa, A. S., de Paola, Â. A. V., Sousa, A. C. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230269 · Cited by 166
Cardiac contractility modulation: a novel approach for the treatment of heart failure
ABI‐SAMRA, F. M., & Gutterman, D. D. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9571-6 · Cited by 90
“combination of an ARB (valsartan) and a neprilysin inhibitor (sacubitril) [15].”
BackgroundThomsen, R. W., Nicolaisen, S. K., Hasvold, P., García‐Sánchez, R., Pedersen, L. H., Adelborg, K., Egfjord, M., Egstrup, K., & Sørensen, H. T. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008912 · Cited by 87
Beta-blockers in COPD: time for reappraisal
Lipworth, B. J., Wedzicha, J. A., Devereux, G. S., Vestbo, J., & Dransfield, M. T. (2016) · European Respiratory Journal · doi:10.1183/13993003.01847-2015 · Cited by 89
“[78] Dual angiotensin/neprolysin inhibition [79] may also confer benefits by augmenting BNP levels and ameliorate the adverse effects of hypoxic pulmonary vasoconstriction.”
BackgroundTsutsui, H., Momomura, S.-I., Saito, Y., Ito, H., Yamamoto, K., Sakata, Y., Desai, A. S., Ohishi, T., Iimori, T., Kitamura, T., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-0854 · Cited by 94
Self-citationKasiakogias, A., Rosei, E. A., Camafort, M., Ehret, G., Faconti, L., Ferreira, J. P., Brguljan-Hitij, J., Januszewicz, A., Kahan, T., Manolis, A. J., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002910 · Cited by 87
“Data from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) and the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced) have supported the…”
BackgroundInfluentialTowards precision medicine in heart failure
Weldy, C. S., & Ashley, E. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00566-9 · Cited by 89
D’Amario, D., Rodolico, D., Rosano, G. M. C., Dahlström, U., Crea, F., Lund, L. H., & Savarese, G. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2477 · Cited by 90
Making Sense of Statistics in Clinical Trial Reports
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.014 · Cited by 86
Self-citationSandhu, A. T., Ollendorf, D. A., Chapman, R. H., Pearson, S. D., & Heidenreich, P. A. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0057 · Cited by 80
“We used losartan as the alternative ARB therapy because it has effects similar to those of valsartan but lower cost (6, 8).”
BackgroundInfluentialKalogeropoulos, A. P., Samman‐Tahhan, A., Hedley, J., McCue, A. A., Bjork, J. B., Markham, D. W., Bhatt, K., Georgiopoulou, V. V., Smith, A. L., & Butler, J. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.02.020 · Cited by 80
“The distribution of demographics, HF characteristics, and comorbidities in our study was similar to that of a recent pivotal trial in HFrEF patients, although our population was more symptomatic (29).”
ResultPrevention of PKG1α oxidation augments cardioprotection in the stressed heart
Nakamura, T., Ranek, M. J., Lee, D. I., Hahn, V. S., Kim, C., Eaton, P., & Kass, D. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80275 · Cited by 79
“These benefits have driven efforts to leverage PKG signaling for the treatment of heart failure, activating the kinase by stimulating cGMP synthesis, reducing natriuretic peptide proteolysis, and/or blocking cGMP hydrolysis (5, 6).”
Morrow, D. A., Velazquez, E. J., DeVore, A. D., PRESCOTT, M. F., Duffy, C. I., Gurmu, Y., McCague, K., Rocha, R., & Braunwald, E. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz240 · Cited by 89
Clements, R., Vang, A., Fernández-Nicolas, A., Kue, N. R., Mancini, T. J., Morrison, A., Mallem, K., McCullough, D. J., & Choudhary, G. (2019) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.005819 · Cited by 79
Straw, S., McGinlay, M., & Witte, K. K. (2021) · Open Heart · doi:10.1136/openhrt-2021-001585 · Cited by 88
“16 It has also been suggested that the trial was additionally biased in favour of the novel agent due to a double drug run-in period of unequal times, in which those randomised to ARNI had already received an ACEi and were therefore pre-selected (20% of patients were lost during the run-in period).”
Pascual-Figal, D. A., Bayés‐Genís, A., Beltrán-Troncoso, P., Caravaca-Pérez, P., Martel, A. C., Crespo-Leiro, M. G., Delgado, J. F., Díez, J., Formiga, F., & Manito, N. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.754499 · Cited by 94
“The study was stopped prematurely after a mean follow-up of 27 months, due to the overwhelming clinical benefit of sacubitril/valsartan over enalapril found in the prespecified interim analysis (5).”
BackgroundMethodInfluentialRakugi, H., Kario, K., Yamaguchi, M., Sasajima, T., Gotou, H., & Zhang, J. Y. (2022) · Hypertension Research · doi:10.1038/s41440-021-00819-7 · Cited by 87
Leyva, F., Zegard, A., Okafor, O., Foley, P. W. X., Umar, F., Taylor, R. J., Marshall, H. J., Stegemann, B., Moody, W. E., Steeds, R. P., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.050 · Cited by 88
Luo, Q., Hu, Y., Chen, X., Luo, Y. K., Chen, J., & Wang, H. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.899746 · Cited by 98
“Although a growing number of medications have been used for heart failure currently, existing treatments target only a fraction of the putative pathophysiological pathways, thus the overall prognosis of heart failure remains unclear (5, 6).”
BackgroundImplications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Newman, J. D., O’Meara, E., Böhm, M., Savarese, G., Kelly, P. R., Vardeny, O., Allen, L. A., Lancellotti, P., Gottlieb, S. S., Samad, Z. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.033 · Cited by 96
Contemporary pharmacological treatment and management of heart failure
Bozkurt, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-00997-0 · Cited by 93
“…novo treatment recommendation is supported by evidence of beneficial effects of ARNIs, such as the reduction in plasma N-terminal pro-B-type natriuretic peptide levels and a reduction in adverse LV remodelling compared with treatment with ACEIs or ARBs in patients hospitalized with HF 6,43,61–63 .”
InfluentialBiomarkers for Heart Failure: An Update for Practitioners of Internal Medicine
Wettersten, N. W., & Maisel, A. S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.01.013 · Cited by 87
Tănase, D. M., Radu, S., Shurbaji, S. A., Baroi, G. L., Costea, C. F., Turliuc, M. D., Ouatu, A., & Floria, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112629 · Cited by 86
Moliner, P., Lupón, J., de Antonio, M., Domingo, M., Santiago‐Vacas, E., Zamora, E., Cediel, G., Santesmases, J., Díez, C., Troya, M. I., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1569 · Cited by 87
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Natriuretic peptide pathways in heart failure: further therapeutic possibilities
Sangaralingham, S. J., Kühn, M., Cannone, V., Chen, H. H., & Burnett, J. C. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac125 · Cited by 88
Fusco, F., Scognamiglio, G., Merola, A., Iannuzzi, A., Palma, M., Grimaldi, N., & Sarubbi, B. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009848 · Cited by 78
Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: For Whom and How
Liga, R., Colli, A., Taggart, D. P., Boden, W. E., & Caterina, R. D. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.026943 · Cited by 92
The Metalloprotease Neprilysin Degrades and Inactivates Apelin Peptides
McKinnie, S. M. K., Fischer, C., Tran, K. M. H., Wang, W., Mosquera, F., Oudit, G. Y., & Vederas, J. C. (2016) · ChemBioChem · doi:10.1002/cbic.201600244 · Cited by 78
Vettel, C., Lindner, M., Dewenter, M., Lorenz, K., Schanbacher, C., Riedel, M., Lämmle, S., Meinecke, S., Mason, F. E., Sossalla, S. T., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.310069 · Cited by 93
Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management
Meagher, P., Adam, M., Civitarese, R., Bugyei‐Twum, A., & Connelly, K. A. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.026 · Cited by 85
Mazurek, J. A., & Jessup, M. L. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.08.001 · Cited by 81
Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?
Vodovar, N., Paquet, C., Mebazaa, A., Launay, J., Hugon, J., & Solal, A. C. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv015 · Cited by 81
“ment of chronic heart failure with reduced ejection fraction (Figure 1).(5) Recently, this beneficial effect on mortality was shown”
BackgroundKorean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 80
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Torrado, J., Cain, C. K., Mauro, A. G., Romeo, F. J., Ockaili, R. A., Chau, V. Q., Nestler, J. A., Devarakonda, T., Ghosh, S., Das, A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.102 · Cited by 88
Rørth, R., Jhund, P. S., Kristensen, S. L., Desai, A. S., Køber, L., Rouleau, J. L., Solomon, S. D., Swedberg, K. B., Zile, M. R., Packer, M., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1359 · Cited by 82
“001 Current smoker, n (%) 156 (14) 94 (12) 0.”
Self-citationKia, D. S., Benza, E., Bachman, T. N., Tushak, C., Kim, K., & Simon, M. A. M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015708 · Cited by 74
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Vedin, O., Sumin, M., Zwiener, I., Hernandez, A. F., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.010 · Cited by 81
Kristensen, S. L., Jhund, P. S., Mogensen, U. M., Rørth, R., Abraham, W. T., Desai, A., Dickstein, K., Rouleau, J. L., Zile, M. R., Swedberg, K., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.117.004409 · Cited by 76
Self-citationHow robust are clinical trials in heart failure?
Docherty, K. F., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw427 · Cited by 83
Self-citationSex Differences in the Coronary System
Taqueti, V. R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77932-4_17 · Cited by 83
Updates in heart failure 30-day readmission prevention
Goldgrab, D., Balakumaran, K., Kim, M. J., & Tabtabai, S. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9754-4 · Cited by 82
2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure
Heidenreich, P. A., Fonarow, G. C., Breathett, K. K., Jurgens, C. Y., Pisani, B., Pozehl, B., Spertus, J. A., Taylor, K. G., Thibodeau, J. T., Yancy, C. W., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.023 · Cited by 86
“The clinical strategy of inhibition of the renin-angiotensin system with ACE inhibitors (Class 1, Level of Evidence: A) (46–51), OR ARBs (Class 1, Level of Evidence: A) (41–44), OR ARNI (Class 1, Level of Evidence: B-R) (45) in conjunction with evidence-based beta blockers (7,33,52), and aldosterone antagonists in sel…”
BackgroundInfluentialHeart Failure in the Last Year: Progress and Perspective
Tomasoni, D., Adamo, M., Anker, M. S., von Haehling, S., Coats, A. J. S., & Metra, M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13124 · Cited by 100
“Along with QRS duration, lower height but not sex played a role in the composite endpoint of all‐cause mortality or first hospitalization for HF.208 In another study, body mass index was associated with outcome: overweight or obese patients receiving CRT with defibrillator were at a lower risk of death compared with u…”
BackgroundInfluentialLiu, X., Li, D., Pi, W., Wang, B., Xu, S., Yu, L., Yao, L., Sun, Z., Jiang, J., & Mi, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109379 · Cited by 90
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 107
Epstein, M. (2016) · Kidney International Supplements · doi:10.1016/j.kisu.2016.01.004 · Cited by 77
Silent Disease Progression in Clinically Stable Heart Failure
Sabbah, H. N. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.705 · Cited by 87
Lindholm, D., James, S. K., Gabrysch, K., Storey, R. F., Himmelmann, A., Cannon, C. P., Mahaffey, K. W., Steg, P. G., Held, C., Siegbahn, A., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.3811 · Cited by 73
Verdonschot, J. A. J., Hazebroek, M. R., Ware, J. S., Prasad, S. K., & Heymans, S. R. B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012514 · Cited by 80
“One of the most recent guideline-changing breakthroughs in general HF treatment was the introduction of the angiotensin receptor-neprilysin inhibitor sacubitril-valsartan.(18) The major PARADIGM (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial show…”
BackgroundThe medical and socioeconomic burden of heart failure: A comparative delineation with cancer
Farmakis, D. T., Stafylas, P. C., Giamouzis, G., Maniadakis, N., & Parissis, J. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.172 · Cited by 84
Geographic Differences in Heart Failure Trials
Ferreira, J. P., Girerd, N., Rossignol, P., & Zannad, F. M. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.326 · Cited by 77
Kusaka, H., Sueta, D., Koibuchi, N., Hasegawa, Y., Nakagawa, T., Lin, B., Ogawa, H., & Kim‐Mitsuyama, S. (2015) · American Journal of Hypertension · doi:10.1093/ajh/hpv015 · Cited by 79
Desai, A. S., Solomon, S. D., Claggett, B. L., McMurray, J. J. V., Rouleau, J. L., Swedberg, K. B., Zile, M. R., Lefkowitz, M. P., Shi, V. C., & Packer, M. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002735 · Cited by 74
Self-citationSenni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Anand, I. S., Duino, V., Sarkar, A., Shi, V. C., & Charney, A. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1054 · Cited by 80
Self-citationKario, K. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0944-4 · Cited by 89
Effects of intentional weight loss in patients with obesity and heart failure: a systematic review
McDowell, K., Petrie, M. C., Raihan, N. A., & Logue, J. (2018) · Obesity Reviews · doi:10.1111/obr.12707 · Cited by 73
“The prevalence of obesity in heart failure with reduced ejection fraction (HFrEF) is between 30% (1) and 40% (2) and in heart failure with preserved ejection fraction (HFpEF) is between 41% (3) and 55% (4).”
BackgroundNeprilysin Inhibition for Heart Failure
McMurray, J. J. V., Packer, M., & Solomon, S. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1412654 · Cited by 72
Self-citationAyalasomayajula, S. P., Langenickel, T., Pal, P., Boggarapu, S., & Sunkara, G. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0543-3 · Cited by 82
“In addition, efficacy and safety were established in the phase III PARADIGM-HF trial [17], wherein sacubitril/valsartan was administered regardless of food intake.”
BackgroundRecent Advances in Antiarrhythmic Drug Therapy
Saljic, A., Heijman, J., & Dobrev, D. (2023) · Drugs · doi:10.1007/s40265-023-01923-3 · Cited by 85
Malgie, J., Wilde, M. I., Clephas, P. R. D., Emans, M. E., Koudstaal, S., Schaap, J., Mosterd, A., van Ramshorst, J., Wardeh, A. J., Wijk, S. S., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3267 · Cited by 86
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
Fala, L. (2015) · Europe PMC (PubMed Central) · Cited by 101
McMurray, J. J. V., Trueman, D., Hancock, E., Cowie, M., Briggs, A. H., Taylor, M. J., Mumby-Croft, J., Woodcock, F., Lacey, M., Haroun, R., et al. (2017) · Heart · doi:10.1136/heartjnl-2016-310661 · Cited by 72
Self-citationNeprilysin Inhibitors and Bradykinin
Campbell, D. J. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00257 · Cited by 72
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure
Kotecha, D., Gill, S. K., Flather, M. D., Holmes, J., Packer, M., Rosano, G., Böhm, M., McMurray, J. J. V., Wikstrand, J., Anker, S. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.059 · Cited by 71
“In more recent trials, no interactions have been noted for renal impairment using this same eGFR cutoff for eplerenone (n 1⁄4 912) or sacubitril-valsartan (n 1⁄4 3,061) (35,36).”
BackgroundSelf-citationRenal protection in chronic heart failure: focus on sacubitril/valsartan
Pontremoli, R., Borghi, C., & Filardi, P. P. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab030 · Cited by 80
“001].(8) The relative risk reduction in CV events with sacubitril/valsartan was similar in patients with and without CKD at baseline [stratified by >_estimated glomerular filtration rate (eGFR)”
Preclinical models of myocardial infarction: from mechanism to translation
Martin, T. P., MacDonald, E. A., Elbassioni, A. A. M., O'Toole, D., Zaeri, A. A. I., Nicklin, S. A., Gray, G. A., & Loughrey, C. M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15595 · Cited by 84
Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
Lam, C. S. P., Mulder, H., Lopatin, Y., Vazquez‐Tanus, J. B., Siu, D., Ezekowitz, J. A., Pieske, B. M., O’Connor, C. M., Roessig, L., Patel, M. J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021094 · Cited by 73
Structure of neprilysin in complex with the active metabolite of sacubitril
Schiering, N., D'Arcy, A., Villard, F., Ramage, P., Logel, C., Cumin, F., Ksander, G. M., Wiesmann, C., Karki, R. G., & Mogi, M. (2016) · Scientific Reports · doi:10.1038/srep27909 · Cited by 72
Novel Therapies for Prevention and Early Treatment of Cardiomyopathies: Now and in the Future
Repetti, G. G., Toepfer, C. N., Seidman, J. G., & Seidman, C. E. (2019) · Circulation Research · doi:10.1161/circresaha.119.313569 · Cited by 77
“An important addition to this armamentarium is LCZ696, a medication that combines sacubitril, an inhibitor of the neutral endopeptidase neprilysin, with the ARB valsartan.(64) Sacubitril increases serum concentrations of natriuretic peptides, bradykinin, and adrenomedullin that can limit the effects of excessive neuro…”
BackgroundMethodWhat Proportion of Patients with Chronic Heart Failure are Eligible for Sacubitril–Valsartan?
Pellicori, P., Urbinati, A., Shah, P. P., Macnamara, A., Kazmi, S., Dierckx, R., Zhang, J., Cleland, J. G. F., & Clark, A. L. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.788 · Cited by 74
“On ACE inhibitor and ARB, n (%) 0 NA 10 (3) NA 0 NA 7 (2) NA”
BackgroundInfluentialHeart failure as a substrate and trigger for ventricular tachycardia
Alvarez, C., Cronin, E. M., Baker, W. L., & Kluger, J. (2019) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-019-00623-x · Cited by 74
Gaziano, T. A., Fonarow, G. C., Velazquez, E. J., Morrow, D. A., Braunwald, E., & Solomon, S. D. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2822 · Cited by 70
“2,4,8-13 The 5 states were (1) inpatient, (2) 1 month after hospitalization, (3) 2 months after hospitalization, (4) more than 2 months after hospitalization for HF, and (5) death.”
BackgroundSelf-citationBekfani, T., Fudim, M., Cleland, J. G. F., Jorbenadze, A., von Haehling, S., Lorber, A., Rothman, A. M. K., Steín, K. M., Abraham, W. T., Sievert, H., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2033 · Cited by 80
Solomon, S. D., Claggett, B. L., McMurray, J. J. V., Hernandez, A. F., & Fonarow, G. C. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.603 · Cited by 72
Self-citationAimo, A., Pateras, K., Stamatelopoulos, K. S., Bayés‐Genís, A., Lombardi, C., Passino, C., Emdin, M., & Georgiopoulos, G. A. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07099-2 · Cited by 74
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.